The India Decade

NPPA orders strict enforcement of lower prices on 137 anti-cancer drugs

State drug controllers must report compliance by 16 November as the Centre moves to ensure affordable cancer care across the country.

By The India Decade

India's drug pricing regulator has ordered state authorities to enforce immediate price cuts across 137 critical anti-cancer medications, warning hospitals, retailers, and manufacturers of strict legal action if they fail to pass the cost savings to patients.

The National Pharmaceutical Pricing Authority (NPPA), which operates under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers, instructed State Drug Controllers to inspect local supply chains and submit action taken reports by 16 November 2026.

Capping margins to protect patients

The policy action follows a government gazette order issued on 17 October 2026, which capped the trade margin on non-scheduled cancer medicines at 30 per cent under a trade margin rationalisation framework. The revised maximum retail prices took effect nationwide on 9 November 2026.

In total, the price caps cover 1,391 specific brands and dosage forms spanning both patented and generic anti-cancer drugs. The list of regulated treatments was compiled following recommendations from an expert committee under the Directorate General of Health Services.

MeasureDetails
Target medications137 non-scheduled anti-cancer drugs
Formulations and brands covered1,391
Maximum allowable trade margin30 per cent
Gazette notification date17 October 2026
Price cut effective date9 November 2026
State compliance report deadline16 November 2026

Mandatory public price displays

Under directives issued by the NPPA, all pharmaceutical manufacturers, stockists, dealers, retailers, hospitals, and healthcare institutions must comply with the lower rates immediately. Establishments are required to display updated price lists prominently on their premises and official websites.

Revised price schedules incorporating company filings received up to 11 November 2026 have been published on the NPPA portal and made accessible through the government's Pharma Sahi Daam mobile app.

Zero tolerance for overcharging

The regulator emphasised that any failure to adhere to the capped rates will trigger overcharging proceedings under the provisions of the Drugs (Prices Control) Order, 2013.

To safeguard consumers, the NPPA has established multiple reporting channels for patients and their families. Members of the public can report instances of overcharging, artificial shortages, or non-availability of medicines through the Pharma Sahi Daam portal, the toll-free helpline (1800-111-255), or by emailing monitoring-nppa@gov.in directly.

Key numbers

WhatFigureSource
Number of anti-cancer drugs capped137NPPA gazette order
Brands and dosage forms affected1,391NPPA office memorandum
Trade margin cap30%Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
Compliance report deadline for states16 November 2026NPPA directive to State Drug Controllers

In this story

NameRole in the story
National Pharmaceutical Pricing AuthorityIssued the enforcement directive and margin caps for anti-cancer drugs.

Topics

The day’s reporting, once each morning. No advertising.

More on this story